렐마다 테라퓨틱스(RLMD)는 NASDAQ에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $4.11 (-2.14%), 시가총액 $0.72B, 52주 최저~최고 $0.51 ~ $7.86.
Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States. The company focuses on the development of NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel, which is in Phase 2 clinical trial for patients with aggressive forms of non-muscle invasive bladder cancer; and Sepranolone, a neurosteroid epimer of allopregnanolone, which is Phase 2b-ready for the potential treatment of prader-willi syndrome, tourette syndrome, excessive tremor, and other diseases related to excessive GABAergic activity. The company has an agreement with Asarina Pharma AB and Trigone. Relmada Therapeutics, Inc. was founded in 2004 and is headquarter
렐마다 테라퓨틱스의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackAll Trade에서 실시간으로 확인할 수 있습니다.
렐마다 테라퓨틱스의 현재 주가는 $4.11 (-2.14%)입니다. BlackAll Trade에서 실시간 시세와 차트를 확인할 수 있습니다.
렐마다 테라퓨틱스의 시가총액은 약 $0.72B입니다.
Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States. The company focuses on the development of NDV-01, a controlled-release intravesical formulation of g